{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:18:54Z","timestamp":1763644734534,"version":"3.45.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Fibroblast growth factor receptor 2 (FGFR2) alterations represent an emerging therapeutic target in gastroesophageal adenocarcinoma (GEA). Although FGFR2\u00a0amplifications and overexpression have been associated with poor prognosis and\u00a0therapeutic resistance, the clinical significant FGFR2 fusions, which are\u00a0exceedingly rare, is unknown. Herein we describe two cases of advanced gastroesophageal and gastric adenocarcinomas characterized by aggressive disease course, rapid progression despite standard first-line chemoimmunotherapy, and the presence of high-level FGFR2 amplification with concurrent WDR11-AS1\u2013FGFR2 fusion detected by circulating tumor DNA (ctDNA) analysis. These cases highlight the genomic complexity and aggressive behavior of FGFR2-driven GEA, underscored by coexisting genetic alterations. The findings emphasize the importance of comprehensive genomic profiling, including both tissue and liquid. in order to capture intratumoral heterogeneity and evolving molecular events. Further investigation of FGFR2 fusion biology and combinatorial therapeutic strategies is warranted to address the clinical challenge of biomarker overlap and treatment resistance in GEA.<\/jats:p>","DOI":"10.3389\/fonc.2025.1686070","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:07:01Z","timestamp":1763644021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic complexity in advanced gastric and esophageal adenocarcinomas: a case report of rare WDR11-AS1-FGFR2 fusions"],"prefix":"10.3389","volume":"15","author":[{"given":"Eric","family":"Mehlhaff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin A.","family":"Deming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaldun","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Welch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Uboha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-022-04162-2","article-title":"Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study","volume":"37","author":"Yasui","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S282718","article-title":"Targeting FGFR2 positive gastroesophageal cancer: current and clinical developments","volume":"15","author":"Gordon","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051117","article-title":"Clinical developments and challenges in treating FGFR2-driven gastric cancer","volume":"12","author":"Lau","year":"2024","journal-title":"Biomedicines"},{"key":"B6","article-title":"Comprehensive identification of FGFR1\u20134 alterations in 5\u2013557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/jca.29184","article-title":"Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11102650","article-title":"Targeting FGFR pathways in gastrointestinal cancers: new frontiers of treatment","volume":"11","author":"Ratti","year":"2023","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115262","article-title":"Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications","volume":"218","author":"Satoh","year":"2025","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.08.005","article-title":"Development and validation of strataNGS, a multiplex PCR, semiconductor sequencing-based comprehensive genomic profiling test","volume":"23","author":"Tomlins","year":"2021","journal-title":"J Mol Diagnostics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae979","article-title":"Database resources of the national center for biotechnology information in 2025","volume":"53","author":"Sayers","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9714570","article-title":"Incidence of FGFR2 amplification and FGFR2 fusion in patients with metastatic cancer using clinical sequencing","volume":"2022","author":"Hyung","year":"2022","journal-title":"J Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7477","DOI":"10.1038\/s41467-022-35144-1","article-title":"Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers","volume":"13","author":"Hsiehchen","year":"2022","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01767-7","article-title":"The two sides of chromosomal instability: drivers and brakes in cancer","volume":"9","author":"Hosea","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2459458","article-title":"Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy","volume":"21","author":"Zhang","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Sig Transduct Target Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:07:02Z","timestamp":1763644022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1686070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":19,"alternative-id":["10.3389\/fonc.2025.1686070"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1686070","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1686070"}}